Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 23, Issue 18, Pages 4215-4224Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2005.05.064
Keywords
-
Categories
Funding
- NCI NIH HHS [CA55909] Funding Source: Medline
Ask authors/readers for more resources
Taking a perspective on available evidence that emphasizes relevance to human disease, cyclin D1 is solidly established as an oncogene with an important pathogenetic role in breast cancer and other human tumors. However, the precise cellular mechanisms through which aberrant cyclin D1 expression drives human neoplasia are less well established. Indeed, emerging evidence suggests that cyclin D1 might act, predominantly or at least in part, through pathways that do not involve its widely accepted function as a cell cycle regulator. Although therapeutic exploitation of the role of cyclin D1 as a molecular driver of breast cancer carries great promise, it is also suggested that direct targeting of the cyclin D1 gene or gene products may prove more successful than approaches that rely on arguably incomplete knowledge of the oncogenic mechanisms of cyclin D1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available